PERTUZUMAB 60 MG/ML + TRASTUZUMAB 60 MG/ML INJ SOL FR 10 ML SC

This tender concerns the procurement of a specific pharmaceutical product: PERTUZUMAB 60 MG/ML + TRASTUZUMAB 60 MG/ML INJ SOL FR 10 ML SC. This refers to a solution for injection in a 10 ml vial, containing Pertuzumab at a concentration of 60 mg/ml and Trastuzumab at a concentration of 60 mg/ml. These are both monoclonal antibody medications commonly used in the treatment of certain types of cancer, particularly HER2-positive breast cancer. The tender is likely issued by a healthcare provider, hospital, or government health agency seeking to purchase this medication. The primary objective is to secure a reliable supply of this critical drug, ensuring its availability for patient treatment. Bidders are expected to provide the specified pharmaceutical product in compliance with all relevant regulatory standards, including quality, safety, and packaging requirements. The tender documents will detail the required quantities, delivery schedules, and any specific storage or handling instructions. Evaluation will likely focus on the supplier's ability to provide the authentic product, meet quality standards, and ensure timely delivery. This procurement is essential for the ongoing medical care of patients requiring this specific therapy.

This is a supplies contract in the health and medical services sector, with a focus on Hospitals and Pharmaceuticals. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 423,370.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.